Cyclo (CLLFVY)

Cyclo (CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7) . cyclo (CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo (CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers[1].

Product Specifications

CAS Number

[1446322-73-1]

UNSPSC

12352209

Target

HIF/HIF Prolyl-Hydroxylase; VEGFR

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cyclo-cllfvy.html

Purity

99.37

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N[C@H]2CC3=CC=C(C=C3)O)=O)=O)=O)=O)[C@H](CS)NC2=O

Molecular Formula

C38H54N6O7S

Molecular Weight

738.94

References & Citations

[1]Miranda E, et al., A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc. 2013 Jul 17;135 (28) :10418-25.